The British Medical Corps, a body subject to executive authority, has given the green light to a vaccine produced by AstraZeneca in cooperation with Oxford. The “Guardian” newspaper said that the required license will open the door to speeding up vaccination, especially in homes for the elderly, where there are thousands of people who are estimated to receive the vaccine.
Below are 5 points you should know about:
The AstraZeneca vaccine is inexpensive and costs approximately 2.5 euros per dose.
The vaccine can also be easily stored at a temperature between two to eight degrees Celsius, unlike the Moderna and Pfizer–Biontech vaccines, which can only be stored for a long time at very low temperatures, which are minus 20 degrees for Moderna and minus 70 degrees for Pfizer.
According to the CEO of AstraZeneca, the vaccine is able to fight the mutated type Coronavirus rampant in Britain. “We believe at the moment that the vaccine should still be effective … but we cannot be sure, so we will do some tests,” Pascal Soriot told the Sunday Times.
This vaccine was developed by the British group AstraZeneca in cooperation with the University of Oxford. It is the second vaccine approved by the British Medicines and Healthcare Products Agency after the Pfizer vaccine, which has been in use since December 8 and has been given to more than 600,000 people.
The United Kingdom, one of the worst-affected countries in Europe, has requested 100 million doses of the AstraZeneca / Oxford vaccine, 40 million of which will be available by the end of March, and vaccinations will begin on January 4.
The company that develops the vaccine says it will be able to manufacture about three billion doses around the world in 2021.
AstraZeneca vaccine is a “viral carrier” vaccine, meaning that another virus has been taken and adapted to fight the Covid-19 virus as a carrier.
This vaccine is the first vaccine whose efficacy has been verified by a scientific journal, the prestigious “The Lancet,” on December 8, and according to the data published by the journal, the vaccine is “safe.”
The side effects of the vaccine are extremely rare at this stage. Of the 23,754 volunteers who participated in the trials, only one patient suffered from “serious side effects likely to be associated” with this injection, according to the magazine.
The case was an inflammation of the spinal cord known scientifically as (transverse myelitis), which prompted the temporary suspension of the experiments in early September.
Error during testing
The British laboratory announced in November that its vaccine was on average 70 percent effective versus more than 90 percent effective for Pfizer and Moderna. This was after unequal experiments conducted on two groups of volunteers.
The vaccine’s effectiveness was 90 percent on volunteers who received half a dose of the first vaccine and a full dose a month later. The second group received a full dose on the first vaccination, then a second full dose a month later, which led to a variation in results.
The company stated that the protocol of the first group that received a half dose was the result of an error and said on November 26 that it would conduct an additional study to verify the results after receiving a number of criticisms.
“We believe that we have found the winning formula and how to achieve high efficiency,” Suriot assured.